Articles

Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma anno 2019

BJH - volume 11, issue 2, march 2020

M. Clauwaert MD, V. Galle MD, M. Maerevoet MD, A. Janssens MD, PhD, K. Saevels MD, S. Snauwaert MD, PhD, C. Springael MD, PhD, V. Van Hende MD, G. Verhoef MD, PhD, F. Offner MD, PhD

SUMMARY

Follicular lymphoma is the most common low-grade non-Hodgkin lymphoma. Survival rates have been rising over time mainly due to advancing therapeutic strategies. As the last Belgian guidelines date from 2012, we present an update of the scientific evidence regarding diagnosis, staging, treatment and follow-up, and confront these to the Belgian reimbursement rules anno 2019. Follicular lymphoma grade 3B is classified as high-grade lymphoma and treated accordingly, and will not be discussed in this paper. Early stage disease can be treated with involved-field radiotherapy, which has curative potential. Advanced stage disease is virtually incurable, but many treatment options are available with good results. In first line, treatment is mostly based on chemotherapy combined with rituximab; the latter can be continued as maintenance therapy. In relapsed setting, introduction of the newer and more potent anti-CD20-antibody obinutuzumab, also in combination with chemotherapy, can lead to improved survival in high-risk patients. For older patients with comorbidities, rituximab monotherapy is the preferred option. In further lines, PI3K-inhibition with idelalisib and radioimmunotherapy are available. Finally, autologous or allogeneic stem cell transplantation remain an option in a small group of selected patients.

(BELG J HEMATOL 2020;11(2):67–74)

Read more

O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

BJH - volume 11, issue Abstract Book BHS, february 2020

W. Daneels , M. Rosskamp , G. Macq , E.I. Saadoon , A. De Geyndt , F. Offner MD, PhD, H. Antoine-Poirel MD, PhD

Read more

BHS guidelines for the treatment of marginal zone lymphomas: 2018 update

BJH - volume 10, issue 4, june 2019

D. Bron MD, PhD, M. Maerevoet MD, E. Van den Neste MD, PhD, V. Delrieu MD, F. Offner MD, PhD, W. Schroyens MD, PhD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, J.B. Giot MD, J.P. Loly MD, A. Janssens MD, PhD, C. Bonnet MD, PhD

Marginal zone lymphomas (MZL) are a heterogeneous subtype of indolent B-non-Hodgkin lymphomas that includes distinct entities:

  • Extranodal mucosa-associated lymphoid tissue lymphoma arises in a variety of tissue but primarily in the stomach. They are usually localised and often associated with chronic antigenic stimulation by microbial pathogens. Eradication of the pathogen is a major part of the first-line therapy. The prognosis is excellent in early stages. In advanced stages, observation, anti-CD20 antibodies and/or cytostatic drugs are therapeutical approaches.
  • Nodal MZL is usually confined in lymph nodes, bone marrow and peripheral blood. The prognosis is somewhat worse in this entity. Current recommendations suggest that they should be managed as follicular lymphomas.
  • Splenic MZL is a unique entity involving the spleen, bone marrow and blood. Hepatitis infection should be eradicated before considering treatment. These lymphomas have an indolent behaviour, and only symptomatic patients should be treated by splenectomy and/or anti-CD20 antibodies.
  • Two novel entities are described, non-chronic lymphocytic leukaemia monoclonal B-cell lymphocytosis, probably closely related to splenic MZL lymphoma, and a less well-defined provisional entity involving primarily the spleen called splenic B-cell lymphoma/leukaemia, unclassifiable, including splenic diffuse red pulp lymphoma and hairy-cell leukaemia variant.

This review will discuss separately the diagnosis, work-up and treatment of extranodal mucosa-associated lymphoid tissue lymphoma, nodal MZL and splenic MZL. These guidelines include the recently published ESMO consensus conference on malignant lymphoma.1–3

(BELG J HEMATOL 2019;10(4):153–64)

Read more

Is it possible to predict who may never need treatment for B-CLL?

BJH - volume 9, issue 3, june 2018

V. Galle MD, P. Vlummens MD, F. Offner MD, PhD

SUMMARY

Chronic lymphocytic leukaemia has a very heterogeneous disease evolution. Prognostic factors of B-CLL overall survival have been extensively studied. However, much less is known about prognostic factors that can identify patients who will never develop an indication for treatment, at the time of their initial diagnosis. In this study we give an overview of variables that have a predictive value for treatment free survival. Subsequently, we try to develop a novel prognostic index, to address the question ‘who will never need treatment for B-CLL?’.

(BELG J HEMATOL 2018;9(3):124–9)

Read more

Vaccine response in patients receiving anti-B-cell targeted therapy

BJH - volume 9, issue 3, june 2018

N. De Wilde , F. Offner MD, PhD

SUMMARY

Infection prevention is of major importance in patients with haematological malignancies, who are immunocompromised because of disease-related and therapy-related factors. However, in patients receiving anti-B-cell therapies, such as rituximab or ibrutinib (an irreversible BTK inhibitor), measures for infection prevention are hardly studied. In this review we considered vaccine response in patients receiving rituximab treatment and we investigated if an adequate vaccine response can be achieved in patients treated with ibrutinib. For rituximab, no protective titers are obtained in patients with haematological malignancies, but in rheumatoid arthritis 30–50% of patients achieve protective titres. Vaccine response following ibrutinib seems low but it is insufficiently studied to make evidence based recommendations.

(BELG J HEMATOL 2018;9(3):113–7)

Read more

PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study

BJH - 2018, issue Abstract Book BHS, february 2018

B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh

Read more

PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?

BJH - 2018, issue Abstract Book BHS, february 2018

V. Galle MD, P. Vlummens MD, F. Offner MD, PhD

Read more
X